{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-010086","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.046090+00:00","generated_at":"2026-06-26T23:06:54.519103+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr Pharma posts $107.9M cash; FDA path for efzofitimod registrational trial in Q3 2022","bullets":["Cash, cash equivalents and investments of $107.9M as of Dec 31, 2021.","FDA End-of-Phase 2 meeting provides development pathway; registrational trial for efzofitimod in pulmonary sarcoidosis planned to start Q3 2022.","Orphan drug designation granted for efzofitimod in sarcoidosis.","ATYR2810 Phase 1 study expected to initiate in H2 2022.","R&D expenses $23.3M in 2021, expected to increase in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-010086","json":"https://secwatch.observer/filing/0001564590-22-010086.json","markdown":"https://secwatch.observer/filing/0001564590-22-010086.md","text":"https://secwatch.observer/filing/0001564590-22-010086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022010086/0001564590-22-010086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459022010086/life-8k_20220314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:06:54.519103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}